Xinmei Shen
Reporter, Technology
Xinmei Shen joined the Post in 2017 and is a technology reporter. She covers content, entertainment, social media and internet culture. Previously, she was with the Post’s tech news site, Abacus. Before that, she was a reporting intern at The Information whilst studying at the University of Hong Kong.
Xinmei Shen joined the Post in 2017 and is a technology reporter. She covers content, entertainment, social media and internet culture. Previously, she was with the Post’s tech news site, Abacus. Before that, she was a reporting intern at The Information whilst studying at the University of Hong Kong.
Areas of Expertise:
China technology coverage, video productionLanguages Spoken:
English, Mandarin
Removal from military-linked entities list eases investor concerns and highlights path for other Chinese firms facing similar challenges.
Financial News says People’s Bank of China halted recent offline events Solana planned to hold in mainland China.
Industry leaders centre discussions on Hong Kong’s soaring asset inflows and safe-haven appeal at major summits this week.
City is still behind the US in tokenisation, but demand is beginning to accelerate, blockchain firm executive says.
Advertisement
Subsidiary of Hong Kong-listed company will present preclinical data on two RNA-based vaccines at major US cancer conference.
CEO predicts investors ‘over-indexed’ to US equities, dollar will divest to Hong Kong, China, Singapore and Switzerland as tensions rise.
Effort aims to ‘bring tokenised gold from sandbox experimentation to scalable, real-value production’, analyst says.
The city says progress has been swift, but industry players say broader adoption and market activity remain key hurdles.
The global AI & Emerging Technology Institute will be based in the Northern Metropolis and is expected to start operations in early 2027.
‘Huge gap’ between supply and demand for technology leads to rapid growth in Indonesia, Malaysia and Thailand, firm says.
Secretary General Teresa Cheng says the expanding hub is ready to step up training and facilitate dialogue amid rising geopolitical tensions.
With the city as a test bed for China’s matrix of digital currencies and transfer services, the yuan’s reach and influence can expand, analysts said.
Hansoh Pharmaceutical, Akeso and others tout positive results as Chinese research accounts for larger percentage of presentations.
Net profit reached 2.46 billion yuan for the quarter, also above analyst estimates.
Licensing deals untouched for now, but proposed US investment rules and new Chinese export curbs may impact biotech expansion, analysts say.
The cryptocurrency is unlikely to climb back above US$100,000 this year as risks remain from interest rate rises to an escalation in Iran.
Company pulls plug after splashy marketing campaign that raised questions given Beijing’s ban on crypto activities.
Veteran banker says start-up aims to help ‘mass affluent’ investors manage portfolios, monitor risks and spot opportunities proactively.
Beijing is attempting to have at least five pharmaceutical products with annual global sales of more than US$1 billion.
US-listed ArriVent lost nearly half its value after a Chinese-licensed cancer drug failed a late-stage trial.
Fresh policy support, falling stocks and rising demand for Chinese bonds shape the week’s market narrative.
Deals involving novel cancer therapies and weight-loss drugs reinforce the growing global appeal of Chinese biotech innovation.
Ministry of State Security warns citizens not to be lured by ‘illusion’ of anonymous transactions.
InnoCare’s pact with Eli Lilly, potentially worth up to US$3.35 billion, highlights a shift towards bigger partnerships, analysts say.
Doctors say more data is needed despite growing interest in detecting multiple cancers from a single blood sample.
China’s ability to conduct clinical trials quickly and cheaply has given it an edge in the biotech sector – and the US is growing concerned.
Stocks jump on reports Washington will allow most licensing deals under ‘substantially softer stance’ than had been feared, analysts say.
New five-year plan aims to turn the sector into a pillar industry by 2030, driven by breakthroughs in technologies across critical fields.
The US central bank raised rates for first time since 2023, Hong Kong followed and Goldman Sachs projects a sharp rise in Chinese firms’ global export share.
